Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Justices Reject Arizona Bid Over Abortion Drugs

By Pharmaceutical Processing | December 15, 2014

WASHINGTON (AP) — The Supreme Court is refusing to allow Arizona to enforce stringent restrictions on medical abortions while a challenge to those rules plays out in lower courts.

The justices on Monday left in place a lower court ruling that blocked rules that regulate where and how women can take drugs that induce abortion. The rules also would prohibit the use of the abortion medications after the seventh week of pregnancy instead of the ninth.

Planned Parenthood was among abortion providers that challenged the rules in federal court. The San Francisco-based 9th U.S. Circuit Court of Appeals prevented the state from putting them in place during the legal challenge. Similar laws are in effect in North Dakota, Ohio and Texas. The Oklahoma Supreme Court struck down the restrictions in that state.

The rules would ban women from taking the most common abortion-inducing drug, mifepristone, after the seventh week of pregnancy. The Food and Drug Administration approved its use in 2000 through the first seven weeks of pregnancy. It is prescribed along with a second drug, misoprostol.

Since the FDA approval, medical researchers and clinical trials have shown that mifepristone is effective in much smaller doses and for two weeks longer in a pregnancy, the challengers said. The second drug also may be taken at home.

Arizona’s rules would require that the drugs be taken only at the doses approved by the FDA in 2000 and only at clinics.

Planned Parenthood says that medical abortions now account for more than 40 percent of abortions at its clinics.

To justify the restrictions, Arizona and the other states have pointed to the deaths of at least eight women who took the drugs. But the 9th circuit said the FDA investigated those deaths and found no causal connection between them and the use of mifespristone or misoprostol.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE